Hepatorenal syndrome-vasoconstrictor or vasodilator?

Xu XiaoYuan; Zheng YingYing

Issue 8

Aug. 2011

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2011 > 27(8): 801-803+817

PDF( 199 KB)

Hepatorenal syndrome-vasoconstrictor or vasodilator?

Published Date: 2011-08-20

Abstract

Abstract

Hepatorenal syndrome (HRS) is a common complication of serious liver disease with a very high mortality, and is characterized by marked reduction in glomerular filtration rate (GFR) and renal plasma flow (RPF) in the absence of other cause of renal failure.The researches of great significance showed that HRS related to renal vasoconstriction with predominant peripheral arterial vasodilation, resulting from complex changes in splanchnic and general circulations as well as systemic and renal vasoconstrictors and vasodilators.Recently, some clinical trials have indicated that vasoconstrictor combined with albumin infusion have emerged as the preferred pharmacologic therapies for management of HRS and could improve short-term outcome.
- hepatorenal syndrome

FullText(HTML)

References(12)

References

[1]Arroyo V, Ginès P, Gerbes AL, et al.Definition and diagnosticcriteria of refractory ascites and hepatorenal syndrome in cirrhosis.International Ascites Club[J].Hepatology, 1996, 23 (1) :164-176.

[2]Salerno F, Gerbes A, Gines P, et al.Diagnosis, prevention andtreatment of hepatorenal syndrome in cirrhosis[J].Gut, 2007, 56 (9) :1310-1318.

[3]Runyon BA.Management of adult patients with ascites due to cirrho-sis:an update[J].Hepatology, 2009, 49 (6) :2087-2107.

[4]European Association for the Study of the Liver.EASL clinical prac-tice guidelines on the management of ascites, spontaneous bacterialperitonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.

[5]Sanyal AJ, Boyer T, Garcia-Tsao G, et al.A randomized, pro-spective, double-blind, placebo-controlled trial of terlipressin fortype 1 hepatorenal syndrome[J].Gastroenterology, 2008, 134 (5) :1360-1368.

[6]Martín-LlahíM, Pépin MN, Guevara M, et al.Terlipressin and al-bumin vs albumin in patients with cirrhosis and hepatorenal syn-drome:a randomized study[J].Gastroenterology, 2008, 134 (5) :1352-1359.

[7]中华医学会.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14 (9) :643-646.

[8]Alessandria C, Venon WD, Marzano A, et al.Renal failure in cir-rhotic patients:role of terlipressin in clinical approach to hepatorenalsyndrome type 2[J].Eur J Gastroenterol Hepatol, 2002, 14 (12) :1363-1368.

[9]Duvoux C, Zanditenas D, Hézode C, et al.Effects of noradrenalinand albumin in patients with type I hepatorenal syndrome:a pilotstudy[J].Hepatology, 2002, 36 (2) :374-380.

[10]Sharma P, Kumar A, Shrama BC, et al.An open label, pilot, ran-domized controlled trial of noradrenaline versus terlipressin in thetreatment of type 1 hepatorenal syndrome and predictors of response[J].Am J Gastroenterol, 2008, 103 (7) :1689-1697.

[11]Skagen C, Einstein M, Lucey MR, et al.Combination treatment withoctreotide, midodrine, and albumin improves survival in patients withtype 1 and type 2 hepatorenal syndrome[J].J Clin Gastroenterol, 2009, 43 (7) :680-685.

[12]Nazar A, Pereira GH, Guevara M, et al.Predictors of response totherapy with terlipressin and albumin in patients with cirrhosis andtype 1 hepatorenal syndrome[J].Hepatology, 2010, 51 (1) :219-226.

Relative Articles

[1]	Rong SUN, Li JIANG. Research advances in biomarkers for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2023, 39(9): 2225-2230. doi: 10.3969/j.issn.1001-5256.2023.09.029
[2]	Jiaqi LIANG, Wen LIU. Integrated traditional Chinese and Western medicine diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2022, 38(9): 1974-1979. doi: 10.3969/j.issn.1001-5256.2022.09.005
[3]	Lihong YANG, Jinhui YANG. Mechanism and treatment of portal-systemic circulatory imbalance in hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2021, 37(12): 2770-2773. doi: 10.3969/j.issn.1001-5256.2021.12.006
[4]	LI Yan, LU LunGen. Emphasis on the basic and clinical research on hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2401-2405. doi: 10.3969/j.issn.1001-5256.2020.11.001
[5]	SONG JingRu, SUN MingYu. Research advances in integrated traditional Chinese and Western medicine therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2561-2564. doi: 10.3969/j.issn.1001-5256.2020.11.037
[6]	LI XiaoYun, HUA Jing. Treatment of hepatorenal syndrome:Vasoconstriction or vasodilation?[J]. Journal of Clinical Hepatology, 2020, 36(11): 2419-2422. doi: 10.3969/j.issn.1001-5256.2020.11.005
[7]	CHEN WenJi, LIANG Wei, ZHOU YongJian. Acute kidney injury and hepatorenal syndrome in end-stage liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2423-2428. doi: 10.3969/j.issn.1001-5256.2020.11.006
[8]	LI Yan, LU LunGen, CAI XiaoBo. Advances in the treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2415-2418. doi: 10.3969/j.issn.1001-5256.2020.11.004
[9]	LIAO XianHua, YE JunZhao, ZHONG BiHui. Pathogenesis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2406-2410. doi: 10.3969/j.issn.1001-5256.2020.11.002
[10]	Chen LanLan, Han Wen, Liu JingJing, Hu Dan, He WeiWei. Research advances in the biomarkers for the early diagnosis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2018, 34(11): 2448-2452. doi: 10.3969/j.issn.1001-5256.2018.11.040
[11]	Song TingXue, Qi XingShun, Gao Fan, Guo XiaoZhong. Advances in diagnosis and treatment of hepatorenal syndrome type of acute kidney injury in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 572-576. doi: 10.3969/j.issn.1001-5256.2017.03.039
[12]	Chen Li, Mei Yong, Yang YiBin, Cao MingYan. Research advances in renal replacement therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2016, 32(3): 605-608. doi: 10.3969/j.issn.1001-5256.2016.03.046
[13]	Gao BaoXiu, He Yong, Li GuiXing, Nie Xin, Luo TongXing, Song HaoLan. Analysis of relationship of chronic severe hepatitis with hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(7): 749-751.
[14]	Chen ShengPeng, He WeiPing, Li YuFang, Wu JiJun. Clinical analysis of misdiagnosis and missed diagnosis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(4): 444-445.
[15]	Wang JiYao. The difficulties in diagnosis and treatment of hepatorenal syndrome-raised by clinical cases[J]. Journal of Clinical Hepatology, 2011, 27(10): 1019-1021.
[16]	Xie YongPeng, Hou Yue, Zang XiuXian, Chu Zhe. The development of treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(5): 558-561.
[17]	Zheng XiaoLi, Wang LiangZhi. Current diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(1): 107-109.
[18]	Fu Qiang, Tang TongYu. Advance in research of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2010, 26(5): 557-560.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (373) PDF downloads(228)

Hepatorenal syndrome-vasoconstrictor or vasodilator?

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Hepatorenal syndrome-vasoconstrictor or vasodilator?

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content